Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma.
The PI3K/PTEN pathway plays a major role in carcinogenesis. Dysregulation of this pathway occurs frequently in breast cancer, and loss of PTEN expression is emerging as a potentially important mechanism of resistance to the widely used anti-HER2 therapy, trastuzumab. However, assays for loss of PTEN expression have suffered from lack of consistency. Here, we describe an automated and reliable protocol for PTEN protein expression by immunohistochemistry in formalin-fixed paraffin-embedded tissue that can be easily incorporated into clinical trials.
Sakr
Rita A
RA
Sloan-Kettering Institute, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Barbashina
Violetta
V
Morrogh
Mary
M
Chandarlapaty
Sarat
S
Andrade
Victor P
VP
Arroyo
Crispinita D
CD
Olvera
Narciso
N
King
Tari A
TA
D001331:Automation; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000175:diagnosis*; D002277:Carcinoma / Q000175:diagnosis* / Q000378:metabolism*; D045744:Cell Line, Tumor; D005260:Female; D005557:Formaldehyde; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods*; D015588:Observer Variation; D051059:PTEN Phosphohydrolase / Q000378:metabolism*; D016612:Paraffin Embedding; D015203:Reproducibility of Results; D013997:Time Factors
D005557:Formaldehyde; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human